Arbutus Biopharma (NASDAQ:ABUS) Releases Earnings Results

Arbutus Biopharma (NASDAQ:ABUS) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.90, FiscalAI reports. The business had revenue of $179.13 million during the quarter, compared to the consensus estimate of $0.75 million. Arbutus Biopharma had a negative net margin of 237.88% and a negative return on equity of 42.39%.

Arbutus Biopharma Stock Performance

Shares of ABUS stock traded down $0.02 on Wednesday, reaching $4.30. 1,002,664 shares of the company were exchanged, compared to its average volume of 2,061,108. The company has a market cap of $845.86 million, a price-to-earnings ratio of -25.26 and a beta of 0.62. The business has a 50-day moving average price of $4.42 and a 200 day moving average price of $4.43. Arbutus Biopharma has a 1 year low of $2.94 and a 1 year high of $5.10.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arbutus Biopharma in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Arbutus Biopharma presently has an average rating of “Hold” and a consensus target price of $5.00.

Institutional Trading of Arbutus Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC increased its stake in shares of Arbutus Biopharma by 48.6% during the fourth quarter. Intech Investment Management LLC now owns 70,563 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 23,074 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Arbutus Biopharma during the fourth quarter worth about $326,000. Los Angeles Capital Management LLC purchased a new stake in shares of Arbutus Biopharma during the fourth quarter worth about $225,000. Sherbrooke Park Advisers LLC increased its stake in shares of Arbutus Biopharma by 71.4% during the third quarter. Sherbrooke Park Advisers LLC now owns 37,073 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 15,439 shares in the last quarter. Finally, Abel Hall LLC purchased a new stake in Arbutus Biopharma during the 4th quarter valued at about $148,000. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.